Primary Biliary Cholangitis Treatment Market Insights
Primary biliary cirrhosis, also known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis include itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat, and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages.
The global primary biliary cholangitis treatment market size was valued at US$ 526.4 million in 2017, and is expected to witness a CAGR of 36.3% during the forecast period (2018 – 2026).
Figure 1. Global Primary Biliary Cholangitis Treatment Market Value Analysis (US$ Mn) and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2019)
Increasing number of pipeline studies is expected to drive the primary biliary cholangitis treatment market growth
Increasing pipeline studies to develop prominent treatments for rare diseases such as primary biliary cholangitis are expected to boost the primary biliary cholangitis treatment market size. For instance, in October 2018, CymaBay Therapeutics, Inc., initiated placebo-controlled and randomized phase 3 clinical trial for seladelpar 5-10mg. The aim of the study was to evaluate safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and to determine inadequate response or intolerance to ursodeoxycholic acid (UDCA). The study is estimated to complete in December 2021.
Moreover, in January 2017, GlaxoSmithKline (GSK) initiated phase 2 clinical trial to study the efficacy, safety, and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). GSK2330672 is a selective inhibitor of human ileal bile acid transporter (IBAT). The study is estimated to complete in April 2020.
Primary Biliary Cholangitis Treatment Market- Regional Analysis
Regional segmentation of the global primary biliary cholangitis treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is anticipated to witness lucrative primary biliary cholangitis treatment market growth, owing to growing initiatives by market players to develop advance treatment options for PBC. For instance, in October 2016, TARGET PharmaSolutions, Inc., U.S.-based Company, in collaboration with Intercept Pharmaceuticals, Inc., launched its TARGET-PBC (Primary Biliary Cholangitis) platform. TARGET-PBC platform has been created to improve the understanding of real world treatment patterns in PBC.
Asia Pacific is also expected to witness significant growth in the primary biliary cholangitis treatment market. For instance, in 2017, the Japanese Biliary Association (JBA) and the Intractable Hepatobiliary Disease Study Group of Japan estimated that there were 2,000 to 3,000 patients with PBC in Japan. Also, in 2017, Japanese researchers planned to collect DNAs from Japanese PSC patients, to examine difference in genetic background between the East and the West of Japan.
Europe is expected to witness significant market share in the market, owing to rising initiative by professional organizations to create awareness among the healthcare professionals to treat the patients suffering from rare diseases such as primary biliary cholangitis. For instance, April 2018, the British Society of Gastroenterology and UK-PBC entered into strategic partnership to develop a comprehensive guidelines for the treatment of primary biliary cholangitis. The guidelines are mainly designed for gastroenterologists and herpetologists engaged in providing treatment to the patients with PBC.
Figure 2: Global Primary Biliary Cholangitis Treatment Market Value (US$ Mn), By Region, 2017
Source: Coherent Market Insights Analysis (2019)
Primary Biliary Cholangitis Treatment Market - Competitive Landscape
Key players operating in the primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and GlaxoSmithKline (GSK) pharmaceutical.
Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.
Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.
Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).
Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2017, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 20 market data tables and 17 figures on “Primary Biliary Cholangitis Treatment Market” - Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.